KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Other Operating Expenses (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Other Operating Expenses for 7 consecutive years, with $18.8 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 88.52% to $18.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$156.3 million through Dec 2025, down 121.34% year-over-year, with the annual reading at -$206.8 million for FY2025, 128.23% down from the prior year.
  • Other Operating Expenses hit $18.8 million in Q4 2025 for Royalty Pharma, up from $12.9 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $924.7 million in Q4 2022 to a low of -$238.0 million in Q2 2021.
  • Historically, Other Operating Expenses has averaged $156.9 million across 5 years, with a median of $153.8 million in 2021.
  • Biggest YoY gain for Other Operating Expenses was 613.05% in 2021; the steepest drop was 548.98% in 2021.
  • Year by year, Other Operating Expenses stood at $272.3 million in 2021, then surged by 239.55% to $924.7 million in 2022, then tumbled by 108.27% to -$76.5 million in 2023, then soared by 314.39% to $164.0 million in 2024, then crashed by 88.52% to $18.8 million in 2025.
  • Business Quant data shows Other Operating Expenses for RPRX at $18.8 million in Q4 2025, $12.9 million in Q3 2025, and -$60.9 million in Q2 2025.